These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 1649059)
1. The concentration-dependent diversity of effects of DNA topoisomerase I and II inhibitors on the cell cycle of HL-60 cells. Del Bino G; Skierski JS; Darzynkiewicz Z Exp Cell Res; 1991 Aug; 195(2):485-91. PubMed ID: 1649059 [TBL] [Abstract][Full Text] [Related]
2. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells. Del Bino G; Darzynkiewicz Z Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159 [TBL] [Abstract][Full Text] [Related]
3. Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells. Hotz MA; Del Bino G; Lassota P; Traganos F; Darzynkiewicz Z Cancer Res; 1992 Mar; 52(6):1530-5. PubMed ID: 1540962 [TBL] [Abstract][Full Text] [Related]
4. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Del Bino G; Bruno S; Yi PN; Darzynkiewicz Z Cell Prolif; 1992 Nov; 25(6):537-48. PubMed ID: 1333822 [TBL] [Abstract][Full Text] [Related]
5. Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay. Gorczyca W; Melamed MR; Darzynkiewicz Z Toxicol Lett; 1993 Apr; 67(1-3):249-58. PubMed ID: 8383887 [TBL] [Abstract][Full Text] [Related]
6. Effect of camptothecin on mitogenic stimulation of human lymphocytes: involvement of DNA topoisomerase I in cell transition from G0 to G1 phase of the cell cycle and in DNA replication. Bruno S; Giaretti W; Darzynkiewicz Z J Cell Physiol; 1992 Jun; 151(3):478-86. PubMed ID: 1338332 [TBL] [Abstract][Full Text] [Related]
7. Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis. Inaba M; Mitsuhashi J; Kawada S; Nakano H Jpn J Cancer Res; 1994 Feb; 85(2):187-93. PubMed ID: 8144400 [TBL] [Abstract][Full Text] [Related]
8. A new action for topoisomerase inhibitors. Zucker RM; Elstein KH Chem Biol Interact; 1991; 79(1):31-40. PubMed ID: 1647887 [TBL] [Abstract][Full Text] [Related]
9. Apoptosis and its modulation in human promyelocytic HL-60 cells treated with DNA topoisomerase I and II inhibitors. Bertrand R; Solary E; Jenkins J; Pommier Y Exp Cell Res; 1993 Aug; 207(2):388-97. PubMed ID: 7688316 [TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells. Ling YH; Andersson BS; Nelson JA Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843 [TBL] [Abstract][Full Text] [Related]
11. Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment. Zucker RM; Adams DJ; Bair KW; Elstein KH Biochem Pharmacol; 1991 Nov; 42(11):2199-208. PubMed ID: 1659821 [TBL] [Abstract][Full Text] [Related]
12. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I. Prost S; Riou G Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110 [TBL] [Abstract][Full Text] [Related]
13. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. D'Arpa P; Beardmore C; Liu LF Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546 [TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes. Kaufmann WK; Boyer JC; Estabrooks LL; Wilson SJ Mol Cell Biol; 1991 Jul; 11(7):3711-8. PubMed ID: 1646393 [TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity. Poot M; Hiller KH; Heimpel S; Hoehn H Exp Cell Res; 1995 May; 218(1):326-30. PubMed ID: 7537696 [TBL] [Abstract][Full Text] [Related]
17. Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro. Backer LC; Allen JW; Harrington-Brock K; Campbell JA; DeMarini DM; Doerr CL; Howard DR; Kligerman AD; Moore MM Mutagenesis; 1990 Nov; 5(6):541-7. PubMed ID: 2175833 [TBL] [Abstract][Full Text] [Related]
18. Two specific topoisomerase II inhibitors prevent replication of human cytomegalovirus DNA: an implied role in replication of the viral genome. Benson JD; Huang ES J Virol; 1988 Dec; 62(12):4797-800. PubMed ID: 2846890 [TBL] [Abstract][Full Text] [Related]
19. Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine. López-Baena M; Mateos S; Piñero J; Trinidad Ortiz ; Cortés F Mutat Res; 1998 Oct; 421(1):109-16. PubMed ID: 9748527 [TBL] [Abstract][Full Text] [Related]
20. The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells. Roberge M; Th'ng J; Hamaguchi J; Bradbury EM J Cell Biol; 1990 Nov; 111(5 Pt 1):1753-62. PubMed ID: 2172257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]